Lesage Anne sold $1.4M of PHVS

Lesage Anne (Chief Early Development) sold 38,472 shares of Pharvaris N.V. (PHVS) at an average of $35.37 ($35.05–$35.48, $1.36M total) across 3 trades over 2026-06-29 to 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lesage Anne
Published Jul 1, 2026, 11:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 11:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Neutral
medium confidence
Mentioned
$PHVS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider liquidity and potential sentiment, but it does not introduce new operational or financial information about PHVS.

02

Market read

A $1.36M planned insider sale is unlikely to be a standalone driver, but it can slightly influence short-term sentiment and positioning.

03

What to watch

Traders may over-weight insider sales; the key is whether there are concurrent news catalysts (none provided here) or unusual follow-on selling beyond planned schedules.

Relevance 5/10Novelty 4/10Timing: Filed July 1, covering sales dated June 29–30

Background

This is an SEC Form 4 insider transaction for Pharvaris N.V. (PHVS), reported by Chief Early Development Lesage Anne.

Company-level read

Ticker impact

$PHVSNeutralMedium confidence
Context

Insider Lesage Anne (Chief Early Development) sold $1.36M of PHVS shares via an open-market sale under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a Form 4 showing a planned sale window and weighted-average prices, but it does not include new company performance, guidance, or regulatory/clinical developments.

Market effects

Minimal; insider-sale disclosures rarely reset sector expectations without accompanying fundamentals.

None indicated; single-company Form 4 filing.

None indicated; no cross-border deal/regulatory event described.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity/compensation mechanics rather than bearish expectations.

Key entities

  • PHVS

    Pharvaris N.V., the company whose shares were sold by an insider.

  • Lesage Anne

    Chief Early Development who executed open-market sales under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.